NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
August 20, 2020 14:11 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of...
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity
August 17, 2020 10:57 ET
|
BioAegis Therapeutics
BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic MORRISTOWN, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing...
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
July 15, 2020 13:34 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
June 23, 2020 17:21 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
May 21, 2020 13:58 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
Ault Life Sciences™ Presents the Todd Ault #KOalz Podcast Interview with Dr. Thomas Wisniewski
May 01, 2020 09:00 ET
|
Ault Life Sciences, Inc.
NEWPORT BEACH, Cal., May 01, 2020 (GLOBE NEWSWIRE) -- Ault Life Sciences™, Inc. (“ALSI” or the “Company”), a Delaware corporation, invites everyone interested in Alzheimer’s disease to watch an...
TRHC Launches First Large Simulation Study to Assess Adverse Drug Events with proposed COVID-19 Treatments
April 29, 2020 07:55 ET
|
Tabula Rasa HealthCare, Inc.
MOORESTOWN, N.J., April 29, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare Corporation® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announced today...
Eagle Health Awarded A Five Year Contract Providing Occupational Medical Services to the NIH
February 07, 2020 16:54 ET
|
Cape Fox FCG
Manasssas, VA, Feb. 07, 2020 (GLOBE NEWSWIRE) -- On January 30, 2020, Eagle Health was awarded a competitive five-year contract providing comprehensive occupational medical services to support the...
BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
January 30, 2020 09:31 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)
January 03, 2020 00:00 ET
|
RadioMedix Inc.
Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National...